Sign In
Buy KRTX
$329.83
+0 (+0%)
At Close: Jun 14, 2024
Karuna Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
12:00am, Wednesday, 03'rd Jun 2020
Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the pote
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote
Why You Shouldn't Bet Against Karuna Therapeutics (KRTX) Stock
01:17pm, Wednesday, 20'th May 2020
Karuna Therapeutics (KRTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Surging Earnings Estimates Signal Good News for Karuna Therapeutics (KRTX)
12:48pm, Wednesday, 20'th May 2020
Karuna Therapeutics (KRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Biotech's Golden Moment As Healthcare Attracts Investors
01:31pm, Tuesday, 12'th May 2020
Biotechs are not as broadly and deeply affected by COVID-19 disruption and now lead the market as the economy begins the recovery process. Healthcare has attrac
Karuna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business Update
10:00am, Thursday, 07'th May 2020
Karuna Therapeutics, Inc. (Nasdaq: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabl
Karuna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business Update
12:00am, Thursday, 07'th May 2020
Karuna Therapeutics, Inc. (Nasdaq: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the pote
Wells softens view on Edwards Lifesciences in premarket analyst action
11:32am, Tuesday, 28'th Apr 2020
Adverum Biotechnologies (NASDAQ:ADVM) initiated with Buy rating and $17 (36% upside) price target at Goldman Sachs.Alector (NASDAQ:ALEC) initiated with Buy rating and $32 (21% upside) price target at
Karuna Therapeutics Appoints Christopher J. Coughlin to its Board of Directors
10:00am, Tuesday, 28'th Apr 2020
Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote
Karuna Therapeutics (KRTX) Gets a Buy Rating from Oppenheimer
08:08pm, Monday, 27'th Apr 2020
Oppenheimer analyst Jay Olson initiated coverage with a Buy rating on Karuna Therapeutics (KRTX) today and set a price target of $125.00. The company's
Karuna Therapeutics (KRTX) Gets a Buy Rating from Oppenheimer
08:08pm, Monday, 27'th Apr 2020
Oppenheimer analyst
Jay Olson
initiated coverage with a
Buy
rating on Karuna Therapeutics (
KRTX
–
Research Report
) today and set a price target of
$125.00
. The company’s shares closed last Mond
The Zacks Analyst Blog Highlights: Livongo Health, Karuna Therapeutics, Sprouts Farmers Market, PennyMac Financial Services and Strategic Education
The Zacks Analyst Blog Highlights: Livongo Health, Karuna Therapeutics, Sprouts Farmers Market, PennyMac Financial Services and Strategic Education
5 Top Mid-Cap Stocks Surging Despite Coronavirus Concerns
11:44am, Saturday, 25'th Apr 2020
The mid-cap specific S&P 400 index has been trending much like its large-cap peers during the coronavirus-induced market turmoil.
5 Top Mid-Cap Stocks Surging Despite Coronavirus Concerns
11:21am, Friday, 24'th Apr 2020
Apart from the large-cap specific three major stock indexes, the mid-cap specific S&P 400 also witnessed a a rally since Mar 23.
